This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /sign-in page

You can view 5 more pages before signing in

Anticholinergic burden (ACB) and cognitive decline

Authoring team

Long-term use of medications with anticholinergic properties has been associated with cognitive and functional decline among older adults.

A study investigated the use of anticholinergic medication and cognitive function (1):

  • participants were evaluated in three study waves (2008‐2010, 2012‐2014, and 2017‐2019)
    • anticholinergic Cognitive Burden (ACB) was calculated based on the medications in use
    • cognitive performance was evaluated using a standardized battery of tests (immediate recall, late recall, recognition, semantic and phonemic verbal fluency, and the trail‐making tests)
  • total of 15,105 participants were recruited and 2,040 were excluded, leaving 13,065 participants whose data were analyzed
    • participants had a mean age of 51.7±9.0 years old, 55% were women, and 53% were white
    • during the follow‐up time, the ACB burden was associated with a decline in global cognition, memory performance and executive function
  • study authors concluded:
    • during eight years of follow‐up, the ACB burden was associated with cognitive decline, particularly in the memory and executive function domains

In study (n=983), higher total daily ACB scale score was associated with poorer integrated cognitive-functional measures in older adults, underscoring the importance of monitoring anticholinergic burden and considering deprescribing to preserve independence (2):

  • based on combined measures in assessing cognitive-functional decline in older adults, this study evidence supports incorporating anticholinergic burden assessment into routine care, particularly for patients aged ≥85 or those with CNS diseases and depression

Anticholinergic medications versus beta-3 adrenergic agonists for overactive bladder (OAB) and dementia risk (3):

  • although concern regarding dementia risk has encouraged prescribing shifts from anticholinergics toward beta-3 adrenergic agonists, a large retrospective cohort study (n = 830,393 adults aged 40 to 90 years newly treated for OAB without preexisting dementia) found no reduction in incident dementia with beta-3 agonists compared with anticholinergics:
  • medication exposures evaluated:
    • high-risk anticholinergics (oxybutynin, tolterodine, or solifenacin)
    • low-risk anticholinergics (darifenacin, trospium, or fesoterodine)
    • beta-3 adrenergic agonists (mirabegron or vibegron)
  • key findings (65,134 incident dementia cases over follow-up):
    • after inverse probability of treatment weighting (IPTW), high-risk anticholinergics were associated with a modestly lower hazard of incident dementia than beta-3 agonists (hazard ratio [HR] 0.90; 95% CI 0.87 to 0.93) and low-risk anticholinergics (HR 0.93; 95% CI 0.90 to 0.96), while low-risk anticholinergics did not differ significantly from beta-3 agonists (HR 0.97; 95% CI 0.93 to 1.01)
    • weighted 10-year dementia risk was 20.0% (95% CI 18.8% to 21.2%) for beta-3 agonists and 18.1% (95% CI 17.9% to 18.3%) for high-risk anticholinergics
    • longer anticholinergic treatment duration was not associated with increased dementia incidence
  • study authors concluded (3):
    • beta-3 agonists were not associated with a lower dementia incidence than anticholinergic medications, and the small observed differences (E-values 1.29 and 1.20) could be explained by modest residual confounding, such as preferential prescribing of beta-3 agonists to patients already perceived to be at cognitive risk (channelling bias)

Reference:

  1. dos Santos ANM, Gonçalves NG, Goulart AC, et al. Anticholinergic burden and cognitive decline: findings from the ELSA-Brasil cohort study. Alzheimers Dement. 2025 Jan 9;20(Suppl 7):e089124. doi: 10.1002/alz.089124.
  2. Raad EB, Ghandour L, Chayaa M, et al. The longitudinal association between anticholinergic burden and cognitive-functional decline among older adults. Br J Clin Pharmacol. 2026 Jan 21. doi: 10.1002/bcp.70457.
  3. Sheyn D, Rhodes S, Mohamed Z, et al. Drug Therapies and Incidence of Dementia Among Adults With Overactive Bladder. JAMA Netw Open. 2026 Nov 6;9(11):e2642026. doi: 10.1001/jamanetworkopen.2026.42026.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.